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Abstract
Background: Oral contraceptives are known to influence the risk of cancers of the female reproductive system. Evidence
regarding the relationship between injectable contraceptives and these cancers is limited, especially in black South Africans,
among whom injectable contraceptives are used more commonly than oral contraceptives.
Methods and Findings: We analysed data from a South African hospital-based case–control study of black females aged
18–79 y, comparing self-reported contraceptive use in patients with breast (n=1,664), cervical (n=2,182), ovarian (n=182),
and endometrial (n=182) cancer, with self-reported contraceptive use in 1,492 control patients diagnosed with cancers with
no known relationship to hormonal contraceptive use. We adjusted for potential confounding factors, including age,
calendar year of diagnosis, education, smoking, alcohol, parity/age at first birth, and number of sexual partners. Among
controls, 26% had used injectable and 20% had used oral contraceptives. For current and more recent users versus never
users of oral or injectable contraceptives, the odds ratios (ORs) for breast cancer were significantly increased in users of oral
and/or injectable contraceptives (OR 1.66, 95% CI 1.28–2.16, p,0.001) and separately among those exclusively using oral
(1.57, 1.03–2.40, p=0.04) and exclusively using injectable (OR 1.83, 1.31–2.55, p,0.001) contraceptives; corresponding ORs
for cervical cancer were 1.38 (1.08–1.77, p=0.01), 1.01 (0.66–1.56, p=0.96), and 1.58 (1.16–2.15, p=0.004). There was no
significant increase in breast or cervical cancer risk among women ceasing hormonal contraceptive use $10 y previously
(p=0.3 and p=0.9, respectively). For durations of use $5 y versus never use, the ORs of ovarian cancer were 0.60 (0.36–0.99,
p=0.04) for oral and/or injectable contraceptive use and 0.07 (0.01–0.49, p=0.008) for injectable use exclusively;
corresponding ORs for endometrial cancer were 0.44 (0.22–0.86, p=0.02) and 0.36 (0.11–1.26, p=0.1).
Conclusions: In this study, use of oral and of injectable hormonal contraceptives was associated with a transiently increased
risk of breast and cervical cancer and, for long durations of use, with a reduced risk of ovarian and endometrial cancer. The
observed effects of injectable and of oral contraceptives on cancer risk in this study did not appear to differ substantially.
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Hormonal contraceptives are among the most commonly used
medications. Worldwide, in 2007, 9% of women aged 15–49 y
were estimated to be using the oral contraceptive pill and 4% were
using injectable contraceptives or implants [1], amounting to over
210 million women exposed to these contraceptive types [2].
Large-scale epidemiological evidence has shown that use of
oral contraceptives significantly affects the risk of cancers of the
liver and of the female reproductive system, specifically cancers of
the breast, cervix uteri, ovary, and endometrium [3,4]. Hence,
the International Agency for Research on Cancer classifies
combined oral contraceptives as carcinogenic to humans,
concluding that there is sufficient evidence of an increased risk
of breast, cervical, and liver cancer in current and recent users
[3,4]. The Agency also states that there is convincing evidence
that women who have used combined oral contraceptives have a
reduced risk of both ovarian and endometrial cancer [3,4]; this
reduction in risk increases with increasing duration of use and
persists for many years after use ceases [3–5]. Furthermore, the
current worldwide evidence indicates that use of combined oral
contraceptives does not significantly influence the risk of any
other cancers [3,4].
Injectable contraceptives are predominantly given as proges-
tagen-only depot preparations—notably, depot medroxyproges-
terone acetate (DMPA, Depo-Provera)—although a small
proportion contain both oestrogen and progestagen [6]. Despite
their approval for use in over 100 countries and their widespread
use since the 1960s, particularly in low income countries,
evidence regarding the relationship between injectable proges-
tagen-only contraceptives and cancer is limited [6]. The data
that are available indicate no material difference in the effect on
breast cancer risk between combined oral contraceptives and
injectable progestagens [7–10], suggesting that injectable con-
traceptive use is likely to increase risk. However, in studies to
date, the individual relative risk estimates for breast cancer in
users of injectable contraceptives exclusively are not significantly
increased [7–10]. Pooled data on cervical cancer, published in
2007, indicate an increase in risk with injectable progestagen
use for 5 y or more [11]. The worldwide evidence regarding
injectable progestagen-only contraceptives indicates a reduction
in the risk of endometrial cancer in users [12,13], and no
significant effect on ovarian cancer [13,14], but these findings
are based on small sample sizes [12–14]. Moreover, since some
women use both combined oral contraceptives and injectable
progestagens during their lifetime, there are difficulties estab-
lishing the independent effects of injectable progestagen
contraceptives on cancer risk. The most recent assessment from
the International Agency for Research on Cancer was in 1999
and hence included much of the relevant data on breast, ovarian,
and endometrial cancer, but not the 2007 data on cervical
cancer; it concluded that there was inadequate evidence in
humans for the carcinogenicity of progestagen-only contracep-
tives [6].
In South Africa, injectable progestagen-only contraceptives
have been used more commonly, and for longer durations, than
anywhere else in the world [1,6,15]. The current analysis was
based on data from a large-scale hospital-based case–control study
of all cancer types in Johannesburg, South Africa [16–18]. The
objective was to investigate the relationship between use of oral
and injectable hormonal contraceptives and cancers of the breast,
cervix uteri, ovary, and endometrium.
Methods
Ethics Statement
The study was approved by the University of the Witwatersrand
Human Research Ethics Committee (Medical).
Overview
This study uses an established case–control design for cancer
epidemiology studies done in resource-limited settings, where cases
are individuals with the cancer of interest and controls are
individuals with other cancers that are not associated with the
exposure under investigation [16–19]. This approach has the
advantage, in such settings, of minimising possible referral bias,
which could result if controls without cancer and/or with other
conditions were selected, in which case there might be underlying
differences in the access to care of cases and controls (see
Discussion). To guard against the possibility that some hitherto
undescribed association between oral and injectable contraceptive
use and a control cancer could materially influence the main
results, sensitivity analyses were conducted systematically exclud-
ing specific cancer types from the control group.
Study Sample
The Johannesburg Cancer Case Control Study is a large
ongoing case–control study recruiting self-defined black (not mixed
race/ancestry) male and female cancer patients with all cancer
types, conducted at the greater Johannesburg public referral
hospitals that offer cancer treatment. Female patients recruited
from 8 March 1995 to 31 December 2006 were included in the
present analysis. Trained nurses used a standard questionnaire to
interview newly diagnosed black cancer patients in their preferred
language (generally Zulu or Sotho). Participants were interviewed
as soon as possible (maximum 6 mo) after diagnosis, prior to
receiving chemotherapy and/or radiotherapy (verified from
medical records). For all analyses, age at and calendar year of
interview are taken as being age at and calendar year of diagnosis.
Socio-demographic and behavioural information was solicited,
including age, birthplace, residence, years of education, alcohol
and tobacco use, reproductive history, and lifetime sexual history.
In the large majority of cases the clinical diagnosis of cancer was
supported by laboratory investigations giving microscopic verifi-
cation. ‘‘Cases’’ for this study were women with a newly diagnosed
invasive breast, cervical, ovarian, or endometrial cancer. Controls
consisted of women diagnosed with cancer types that have no
known relationship to oral or injectable contraception, based on
data from the International Agency for Research on Cancer [4,6]
and the authors’ knowledge of the area. Excluded from the
controls were women with cancers of the liver and biliary system
(n=52); other genital cancers (total n=213: vulva [n=125],
vagina [n=22], placenta [n=32], other [n=34]); Kaposi sarcoma
(n=278), because of its overwhelming association with HIV and
because its preponderance among women in HIV-positive
individuals suggests that some hormonal factors may be at play;
and cancers of ill-defined, secondary, or unspecified sites (n=157),
because they could not be assigned to be cases or controls.
Classification of Use of Hormonal Contraceptives
Women were asked separately about oral and injectable
contraceptives: (1) Have you ever taken them? (2) If yes, how
old were you when you started taking them? (3) If yes, how old
were you when you stopped taking them? (4) If yes, how long in
total did you take them? Women reported their age at starting and
stopping contraceptives in whole years, while the reporting of
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different contraceptives take to be eliminated from a woman’s
body, in recording of duration of use, 1 mo was added to the date
of the last prescription for oral contraceptives, and 2 or 3 mo were
added to the time of the last injection for injectable contraceptives,
depending on the preparation used. Responses to question 1
indicated whether the patient had ever used oral and/or injectable
contraceptives. Responses to question 3 combined with age at
cancer diagnosis (i.e., the approximate time of recruitment into the
study) provided the number of years since last use of oral and/or
injectable contraceptives.
Discrete categories were then created for users of oral
contraceptives exclusively, users of injectable contraceptives exclu-
sively, users of both oral and injectable contraceptives, and users of
oral and/or injectable contraceptives. ‘‘Users of oral contraceptives
exclusively’’ was defined as women who reported ever having used
oral contraceptives but never having used injectable contraceptives.
‘‘Users of injectable contraceptives exclusively’’ was defined as
women who reported everhaving used injectable contraceptives but
never having used oral contraceptives. ‘‘Users of both oral and
injectable contraceptives’’ was defined as women who reported ever
having used both oral and injectable contraceptives, and ‘‘users of
oral and/or injectable contraceptives’’ was a combined group
including women who reported having used either or both oral and
injectable contraceptives. For these last two groups, time since last
use was calculated as time since last reported use of either oral or
injectable contraceptives, and duration of use was calculated by
adding together the total amount of time that either oral or
injectable use was reported. For each of the use categories, variables
were then constructed as follows: ever use (ever versus never), total
duration of use (never, ,5y ,$5 y), and time since last use (never,
,10 y, $10 y). The categories used in these variables were defined
a priori and were broadly based on those used in prior analyses, for
oral contraceptives, taking into account the sample size in the
relevant categories [5,7,11].
Based on the most recent meta-analyses of the worldwide
evidence, we hypothesised that recency of use of hormonal
contraceptives would be most important for cancers of the breast
and cervix, i.e., that increased risks would be seen in current and
recent users [7,11]. We also hypothesised, based on prior analyses
for oral contraceptives, that for cancers of the ovary and
endometrium, duration of use would be most important and that
reductions in risk would be more likely to be seen in women who
had used hormonal contraceptives for long periods of time [4,5].
The analyses were structured to take account of these hypotheses,
focusing on time since last use for analyses relating to cancers of
the breast and cervix and on duration of use for cancers of the
ovary and endometrium.
For this study, oral contraceptives were assumed to be
combined oestrogen-progestagen oral contraceptives, as progesta-
gen-only pills distributed in South African public sector clinics are
recommended only for breastfeeding women [20]; the data
collection did not distinguish between oral combined and oral
progestagen-only contraceptives. Injectable contraceptives were
assumed to be progestagen-only preparations. More detailed data
from 111 consecutive injectable contraceptive users taking part in
this study, with contraceptive use over the relevant time period,
showed that 80% had used DMPA only, 12% had used
norethisterone oenanthate only, and 8% had used DMPA and
norethisterone oenanthate (unpublished data).
Statistical Methods
Evidence regarding the relationship of potential confounding
factors to the outcomes of interest was obtained from the relevant
published evidence, e.g., [5,21]. The distribution of responses for
potential confounding variables according to use of oral and
injectable contraceptives was tabulated for cases and controls. For
each of the four ‘‘case’’ cancer types, separate multivariable
unconditional logistic regression models were fitted to the data.
The relationships between hormonal contraceptives and the
specific cancer types were examined according to ever use,
recency of use, and duration of use.
In order to investigate independently the effects of oral and
injectable contraceptive use, the estimated odds ratios (ORs) for
specific cancer types were presented for users of oral contracep-
tives exclusively, users of injectable contraceptives exclusively,
users of both oral and injectable contraceptives, and users of oral
and/or injectable contraceptives. Women who had never used
either oral or injectable hormonal contraceptives were used as the
reference group throughout. Cancer-specific multivariable uncon-
ditional binary logistic regression models were fitted to the data,
and separate models were fitted for non-mutually exclusive
categories of contraceptive use (e.g., ‘‘both oral and injectable’’
and ‘‘oral and/or injectable’’).
All multivariable unconditional logistic regression models were
adjusted for age at diagnosis (18–29, 30–34, 35–39,…, 75–79 y,
with the two youngest age groups combined for the endometrial
cancer analyses to remove a zero cell); year of diagnosis (1995,
1996,…, 2006); years in full-time education (0–4 y, 5–7 y, 8+ y);
smoking status (never versus ever); alcohol use (ever versus never—
in this population a substantial proportion of women were lifetime
non-drinkers); parity/age at first birth (no live births, 1–3 live
births/,21 y of age at first birth, .3/,21, 1–3/21+, .3/21+);
area of residence (rural versus urban); province of birth (Gauteng,
Limpopo, Free State, KwaZulu Natal, Mpumalanga, Northwest,
Eastern Cape, other); and lifetime number of sexual partners (0–1,
2–5, 6+) (0 and 1 sexual partners were combined into one category
because only 14 women had reported having had no sexual
partners). Wald tests for heterogeneity and corresponding p-
values—referred to here as p(heterogeneity)—were used to
compare the associations between oral contraceptive and inject-
able contraceptive use and risk of specific cancers, and to examine
effects according to duration of use and time since last use.
HIV infection is a potential confounder in the relationship
between hormonal contraceptives and cervical cancer; data on
HIV status, based on serological testing of blood collected at the
time of interview, was available for 90% of study participants. We
conducted sensitivity analyses of the effect of additional adjustment
for HIV status in this relationship. However, because additional
adjustment for HIV did not materially affect the OR estimates for
hormonal contraceptives and cervical cancer (see Results), and
because HIV infection is not considered a potential confounder in
the relationship between hormonal contraceptives and breast,
ovarian, and endometrial cancers, HIV status was not included in
the primary analysis models.
The estimated ORs for cervical cancer were not adjusted for
history of cervical cancer screening (Pap smears) because this item
was added to the study questionnaire in 2001 and is missing for
61% of participants. We did, however, conduct sensitivity analyses
using the reduced complete-case datasets whilst additionally
adjusting for cervical smear history in the analysis of cervical
cancer, and we also performed analyses on the full dataset after
multiple imputation of the unobserved Pap smear histories. Briefly,
this involved imputing missing Pap smear histories (‘‘never/this
illness only’’ versus ‘‘yes before this illness’’) of cervical cancer and
control patients 20 times using a binary logistic imputation model.
Predictors in the imputation model included all confounders
included in the primary analysis models, time since last
Hormonal Contraceptives and Cancer in South Africa
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injectable, injectable ,10 y/never oral, oral and injectable ,10 y,
oral $10 y/never injectable, injectable $10 y/never oral, oral
and injectable $10 y) and also the participant’s disease status
(cervical cancer case or control). The analysis models for the
multiply imputed data contained the same covariates as those in
the corresponding primary analysis models with additional
adjustment for Pap smear history (‘‘never/this illness only’’ versus
‘‘yes before this illness’’).
The effect of systematically excluding each control cancer type,
in turn, from the control group on the estimated OR for the main
exposure–outcome relationships of interest was also examined.
All analyses were performed using Stata 11.0 software
(StataCorp).
Results
For the study period, there was a total of 5,702 study
participants with full information on the exposures and risk
factors of interest. This sample included women with newly
diagnosed invasive breast (n=1,664), cervical (n=2,182), ovarian
(n=182), or endometrial (n=182) cancer. There were 1,492
controls, comprising patients with other types of invasive cancers
not known to be influenced by hormonal contraceptive use, as
described in Methods. There were numerous cancer types among
the controls, with the most common types being oesophageal
cancer (n=301), colon and rectal cancer (n=163), non-Hodgkin
lymphoma (n=125), and lung cancer (n=118).
Compared with women who had never used hormonal
c o n t r a c e p t i v e s ,u s e r sw e r e ,o na v e r a g e ,y o u n g e r ,m o r ee d u c a t e d ,
and less likely to live in a rural area (Table 1). Users were less
likely than non-users, on average, to have ever smoked, to have
consumed alcohol, to have one or no sexual partners, and to
have had more than three live births. These differences were
similar when comparing users and non-users of oral contracep-
tives and when comparing users and non-users of injectable
contraceptives.
Table 2 shows the distribution of hormonal contraceptive usage
patterns and adjusted ORs for the specific cancer types,
comparing women who had ever used hormonal contraceptives
with those who had never used them. Among controls, 37% had
ever used oral and/or injectable contraceptives, 20% were
classified as ever users of oral contraceptives, 10% were users of
oral contraceptives exclusively, 26% were ever users of injectable
contraceptives, and 17% were users of injectable contraceptives
exclusively. Overall, 49% and 44% of the women with breast or
cervical cancer had ever used injectable and/or oral contracep-
tives respectively, whereas 26% of the women with ovarian cancer
had used hormonal contraceptives, and 17% of women with
endometrial cancer had used them.
The risk of breast cancer was significantly increased among
women who had ever used oral and/or injectable contraceptives,
compared to never users of hormonal contraceptives, and the risk
of ovarian cancer was significantly reduced among such ever users
(Table 2). To test our a priori hypotheses, emphasis was placed
initially on time since last use of hormonal contraceptives for
analyses relating to breast and cervical cancer, and on duration of
use for ovarian and endometrial cancer. There were relatively few
cases of cancers of the ovary and endometrium, so power was
limited.
Breast Cancer
The risk of breast cancer was significantly increased (OR 1.66,
95% CI 1.28–2.16, p,0.001) in women who had used either
oral or injectable contraceptives within the previous 10 y and
did not differ significantly (OR 1.11, 0.91–1.36, p=0.3)inthose
ceasing use $10 y previously, compared to women who had
never used hormonal contraceptives (Figure 1A). There was no
significant difference in risk between users of oral contraceptives
exclusively, users of injectable contraceptives exclusively, and
users of both in the last 10 y, with ORs of 1.57 (1.03–2.40), 1.83
(1.31–2.55), and 1.50 (1.04–2.17), respectively (Figure 1A;
p[heterogeneity]=0.6). In women who had used either or both
preparations, this elevated risk declined significantly with
increasing time since last use of hormonal contraceptives
(p=0.004) but was not significantly related to duration of use
(p=0.4)(Table3).
Table 1. Demographic and risk factor characteristics of case and control participants, according to use of hormonal
contraceptives.
Characteristic
Never Used Hormonal
Contraceptives
Ever Used Oral
Contraceptives, Never
Used Injectable
Contraceptives
Ever Used Injectable
Contraceptives, Never
Used Oral Contraceptives
Ever Used Oral and/or
Injectable Contraceptives
Cases
(n=2,365)
Controls
(n=946) Cases (n=537)
Controls
(n=156) Cases (n=838)
Controls
(n=249)
Cases
(n=1,845)
Controls
(n=546)
Age 56 60 49 48 44 39 45 43
Years of education 7 7 9 9 9 9 9 9
1 or no sexual partners 413 (17.5%) 201 (21.2%) 53 (9.9%) 18 (11.5%) 76 (9.1%) 33 (13.3%) 163 (8.8%) 67 (12.3%)
Lives in rural area 567 (24.0%) 188 (19.9%) 76 (14.2%) 22 (14.1%) 155 (18.5%) 35 (14.1%) 290 (15.7%) 74 (13.6%)
Ever tobacco smoker 560 (23.7%) 293 (31.0%) 85 (15.8%) 22 (14.1%) 121 (14.4%) 52 (20.9%) 280 (15.2%) 94 (17.2%)
Ever drink alcohol 1,001 (42.3%) 418 (44.2%) 189 (35.2%) 47 (30.1%) 317 (37.8%) 97 (39.0%) 692 (37.5%) 199 (36.4%)
.3 live births 1,076 (45.5%) 453 (47.9%) 200 (37.2%) 61 (39.1%) 375 (44.7%) 79 (31.7%) 773 (41.9%) 196 (35.9%)
Aged $21 y at first birth 1,079 (45.6%) 432 (45.7%) 261 (48.6%) 80 (51.3%) 376 (44.9%) 111 (44.6%) 837 (45.4%) 252 (46.2%)
Born in Gauteng Province 921 (38.9%) 355 (37.5%) 277 (51.6%) 87 (55.8%) 333 (39.7%) 119 (47.8%) 833 (45.1%) 271 (49.6%)
Recruitment year 2001–2006 1,109 (46.9%) 429 (45.3%) 308 (57.4%) 93 (59.6%) 545 (65.0%) 156 (62.7%) 1,170 (63.4%) 351 (64.3%)
Age and education data are medians; all other data are n (percent).
doi:10.1371/journal.pmed.1001182.t001
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Compared with women who had never used hormonal
contraceptives, women who had used oral and/or injectable
contraceptives within the previous 10 y had a significantly elevated
risk of cervical cancer (OR 1.38, 1.08–1.77, p=0.01), while those
ceasing use $10 y previously had no significant difference in risk
(OR 1.01, 0.84–1.22, p=0.9) (Figure 1B). The magnitude of the
increase in cervical cancer risk did not differ significantly between
users of oral contraceptives exclusively, users of injectable
contraceptives exclusively, and users of both, in the last 10 y
(p[heterogeneity]=0.2); the risk in recent users of injectable
contraceptives exclusively was significantly increased, compared to
Table 2. Frequencies and adjusted odds ratios for breast, cervical, ovarian, and endometrial cancer according to ever/never oral
and injectable contraceptive use combinations.
Contraceptive Use Control Breast Cancer Cervical Cancer Ovarian Cancer Endometrial Cancer
n (Percent) n (Percent) OR (95% CI) n (Percent) OR (95% CI) n (Percent) OR (95% CI) n (Percent) OR (95% CI)
Total 1,492 (100%) 1,664 (100%) 2,182 (100%) 182 (100%) 182 (100%)
Never injectable or oral
contraceptive user
946 (63%) 856 (51%) 1.00 1,223 (56%) 1.00 135 (74%) 1.00 151 (83%) 1.00
Ever oral, never
injectable
156 (10%) 256 (15%) 1.28
(1.00, 1.64)
241 (11%) 0.97
(0.76, 1.24)
23 (13%) 0.88
(0.52, 1.50)
17 (9%) 1.01
(0.55, 1.85)
Ever injectable,
never oral
249 (17%) 344 (21%) 1.31
(1.03, 1.65)
474 (22%) 1.23
(0.99, 1.53)
10 (5%) 0.35
(0.17, 0.71)
10 (5%) 0.69
(0.33, 1.46)
Ever injectable,
ever oral
141 (9%) 208 (13%) 1.17
(0.89, 1.54)
244 (11%) 1.12
(0.86, 1.45)
14 (8%) 0.69
(0.36, 1.32)
4 (2%) 0.39
(0.13, 1.12)
Ever injectable
and/or ever oral
546 (37%) 808 (49%) 1.26
(1.05, 1.52)
959 (44%) 1.12
(0.94, 1.33)
47 (26%) 0.63
(0.41, 0.97)
31 (17%) 0.75
(0.45, 1.22)
OR adjusted for age at diagnosis, year of diagnosis, education, tobacco smoking, alcohol consumption, parity/age at first birth, number of sexual partners, urban/rural
residence, and province of birth, where appropriate.
doi:10.1371/journal.pmed.1001182.t002
Figure 1. Odds ratio for breast and cervical cancer in relation to use of hormonal contraceptives, according to time since last use.
Adjusted ORs (95% CI) for (A) breast cancer and (B) cervical cancer in relation to use of oral and injectable contraceptives, adjusted for age at
diagnosis, year of diagnosis, education, tobacco smoking, alcohol consumption, parity/age at first birth, number of sexual partners, urban/rural
residence, and province of birth. Squares represent ORs, and horizontal lines indicate 95% CI. Diamonds represent the ORs and confidence intervals
for the group comprising women from all three exposure categories immediately above.
doi:10.1371/journal.pmed.1001182.g001
Hormonal Contraceptives and Cancer in South Africa
PLoS Medicine | www.plosmedicine.org 5 March 2012 | Volume 9 | Issue 3 | e1001182women who had never used hormonal contraceptives (OR 1.58,
1.16–2.15, p=0.004) (Figure 1B). Risk diminished significantly
with increasing time since last use of oral and/or injectable
contraceptives (p=0.02), but was not significantly related to
duration of use (p=0.96) (Table 3).
Ovarian Cancer
The risk of ovarian cancer did not differ significantly between
women who had never used hormonal contraceptives and those
who had used oral and/or injectable contraceptives for a total of
less than 5 y (OR 0.69, 0.39–1.21, p=0.2) (Figure 2A). For those
using hormonal contraceptives for a total of $5 y, the risk of
ovarian cancer was significantly reduced (OR 0.60, 0.36–0.99,
p=0.04) (Figure 2A) compared to never users, but there was no
significant difference in the overall risk of ovarian cancer by
duration of use (p=0.7) or by time since last use (p=0.97) for oral
and/or injectable contraceptives (Table 4). The sample sizes are
too small for reliable comparisons by type of contraceptive used;
however, significant reductions in ovarian cancer risk were
observed in ever users (OR 0.35, 0.17–0.71, p=0.004) (Table 2)
and long-duration users of injectable contraceptives exclusively
(OR 0.07, 0.01–0.49, p=0.008, based on one exposed case),
compared with never users of hormonal contraceptives (Figure 2A).
Endometrial Cancer
Compared with women who had never used hormonal
contraceptives, women who used oral and/or injectable contra-
ceptives for a total of 5 y or longer had a significantly lower risk of
endometrial cancer (OR 0.44, 0.22–0.86, p=0.02); women who
used these contraceptives for less than 5 y had no significant
difference in risk (OR 1.28, 0.71–2.32, p=0.4) (p[heterogeneity]
for duration=0.007) (Figure 2B). The sample sizes are too small to
test for differences by further subdividing the data.
Sensitivity Analyses
Additional adjustment for the number of previous Pap smears
(using multiply imputed data) and for HIV status had no material
effect on the OR for cervical cancer in relation to recent or past
use of hormonal contraceptives (see Figures S1 and S2). Exclusion
of individual cancer types from the control group had no material
effect on the OR for cancers of the breast and cervix in recent and
past versus never users of hormonal contraceptives, nor did it
change materially the ORs for cancers of the ovary and
endometrium in long- and short-duration users of hormonal
contraceptives, compared with never users (see Figures S3, S4, S5,
S6).
Discussion
This study was conducted among black women in South Africa.
Use of injectable contraceptives was very common, with over one-
quarter of the controls in the study reporting they had used them
at some point in their lives. In contrast to most of the rest of the
world, use of injectable contraceptives was more common than use
of oral contraceptives, and was often for long durations.
The study shows that the risk of breast cancer and cervical
cancer is increased significantly among women who are current
and recent users of oral and/or injectable contraceptives and,
separately, among current and recent users of injectable
contraceptives exclusively. The elevated risk diminishes following
cessation of use, such that no significant increase in risk is present
$10 y after ceasing use. Risk is not significantly related to
duration of use and does not differ significantly between users of
oral and injectable contraceptives.
There were far fewer cases of ovarian and endometrial cancer
(182 cases of each, respectively) than breast and cervical cancer
(about 2,000 cases of each), thus limiting statistical power.
Nevertheless, we found that women who had used oral and/or
injectable contraceptives for a duration of $5 y had significantly
reduced risks of both ovarian and endometrial cancer compared
with women who had never used hormonal contraceptives.
Our results show a significantly increased breast cancer risk in
women who in the previous 10 y used injectable contraceptives
exclusively (OR 1.83, 1.31–2.55) compared with women who have
never used hormonal contraceptives, based on 186 exposed cases.
These findings add substantially to the previously available
evidence. The most comprehensive summary of worldwide
Table 3. Adjusted odds ratios for breast and cervical cancer, according to time since last use and duration of use of oral and
injectable contraceptives.
Contraceptive Use Control Breast Cancer Cervical Cancer
n (Percent) n (Percent) OR (95% CI) n (Percent) OR (95% CI)
Total 1,492 (100%) 1,664 (100%) 2,182 (100%)
Never oral or injectable contraceptive user 946 (63%) 856 (51%) 1.00 1,223 (56%) 1.00
Oral and/or injectable contraceptive user
Time since last use ,10 y overall 251 (17%) 399 (24%) 1.66 (1.28, 2.16) 428 (20%) 1.38 (1.08, 1.77)
Duration ,5 y 77 (5%) 70 (4%) 1.72 (1.09, 2.70) 87 (4%) 1.43 (0.94, 2.18)
Duration $5 y 174 (12%) 329 (20%) 1.65 (1.26, 2.17) 341 (16%) 1.37 (1.05, 1.78)
Time since last use $10 y overall 295 (20%) 409 (25%) 1.11 (0.91, 1.36) 531 (24%) 1.01 (0.84, 1.22)
Duration ,5 y 148 (10%) 222 (13%) 1.23 (0.96, 1.58) 286 (13%) 1.03 (0.81, 1.30)
Duration $5 y 147 (10%) 187 (11%) 1.00 (0.77, 1.29) 245 (11%) 1.00 (0.78, 1.27)
p(heterogeneity)—time since last use 0.004 0.02
p(heterogeneity)—duration
a 0.4 0.96
All ORs adjusted for age at diagnosis, year of diagnosis, education, tobacco smoking, alcohol consumption, parity/age at first birth, number of sexual partners, urban/
rural residence, and province of birth.
aHeterogeneity for duration ,5 y versus $5 y, within the two categories for time since last use.
doi:10.1371/journal.pmed.1001182.t003
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contraceptives was published by the Collaborative Group on
Hormonal Factors in Breast Cancer in 1996 [7]. This pooled
analysis found a relative risk of breast cancer of 1.17 (standard
deviation=0.13), based on 137 women with breast cancer who
had used injectable progestagens within the previous 5 y,
Figure 2. Odds ratio for ovarian and endometrial cancer in relation to use of hormonal contraceptives, according to duration of
use. Adjusted OR (95% CI) for (A) ovarian cancer and (B) endometrial cancer in relation to use of oral and injectable contraceptives, adjusted for age
at diagnosis, year of diagnosis, education, tobacco smoking, alcohol consumption, parity/age at first birth, number of sexual partners, urban/rural
residence, and province of birth. Squares represent ORs, and horizontal lines indicate 95% CI. Diamonds represent the ORs and confidence intervals
for the group comprising women from all three exposure categories immediately above.
doi:10.1371/journal.pmed.1001182.g002
Table 4. Adjusted odds ratios for ovarian and endometrial cancer, according to duration of use and time since last use of oral and
injectable contraceptives.
Contraceptive Use Control Ovarian Cancer Endometrial Cancer
n (Percent) n (Percent) OR (95% CI) n (Percent) OR (95% CI)
Total 1,492 (100%) 182 (100%) 182 (100%)
Never oral or injectable contraceptive user 946 (63%) 135 (74%) 1.00 151 (83%) 1.00
Oral and/or injectable contraceptive user
Duration ,5 y overall 225 (15%) 19 (10%) 0.69 (0.39, 1.21) 19 (10%) 1.28 (0.71, 2.32)
Time since last use ,10 y 77 (5%) 4 (2%) 0.77 (0.22, 2.71) 0 (0%) Insufficient data
Time since last use $10 y 148 (10%) 15 (8%) 0.67 (0.36, 1.23) 19 (10%) 1.39 (0.77, 2.52)
Duration $5 y overall 321 (22%) 28 (15%) 0.60 (0.36, 0.99) 12 (7%) 0.44 (0.22, 0.86)
Time since last use ,10 y 174 (12%) 13 (7%) 0.59 (0.29, 1.18) 5 (3%) 0.51 (0.19, 1.43)
Time since last use $10 y 147 (10%) 15 (8%) 0.61 (0.33, 1.12) 7 (4%) 0.39 (0.17, 0.89)
p(heterogeneity)—time since last use
a 0.97 0.7
p(heterogeneity)—duration 0.7 0.007
All ORs adjusted for age at diagnosis, year of diagnosis, education, tobacco smoking, alcohol consumption, parity/age at first birth, number of sexual partners, urban/
rural residence, and province of birth.
aHeterogeneity for time since last use ,10 y versus $10 y, within the two duration categories for ovarian cancer and within duration $5 y for endometrial cancer.
doi:10.1371/journal.pmed.1001182.t004
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small excess risk was non-significant, and results for users of
injectable contraceptives exclusively were not given [7,22].
Another study, published in 2000 and conducted in South Africa,
showed a significant increase in breast cancer risk among current
users of injectable contraceptives compared to never users of
hormonal contraceptives (OR 1.6, 1.1–2.3, based on 65 exposed
cases), but no results were presented for current users who had
exclusively used injectable contraceptives [10].
The pooled analysis on injectable contraceptive use and the
risk of cervical cancer from the International Collaboration of
Epidemiological Studies of Cervical Cancer [11] included data
on 453 exposed cases, many of whom were also exposed to oral
contraceptives. Restricting the analysis to women who had
n e v e ru s e dc o m b i n e do r a lc o n t r a c e p t i v e s ,t h o s ew i t h$5yo fu s e
of injectable contraceptives had a relative risk of cervical cancer
of 1.23 (1.00–1.54), compared with never users. Our finding of
an OR of cervical cancer of 1.58 (1.16–2.15) among current and
more recent users of injectable contraceptives (i.e., use within
the past 10 y) exclusively is consistent with this, but we also
found that the significant excess in risk is no longer present in
w o m e nm o r et h a n1 0 ya f t e rt h e i rl a s tu s eo fi n j e c t a b l e
contraceptives.
Our finding of a significantly protective effect of the exclusive
use of injectable contraceptives for $5 y on ovarian cancer is
based on one exposed case only. However, our results are
consistent with the non-significant results of the two previous
studies we identified in this area, which together included only two
cases exposed to injectable contraceptives exclusively [13,14]. The
most comparable study, the 1991 World Health Organization
study [14], found an OR of ovarian cancer in ever users of DMPA
exclusively of 0.3 (0.1–1.2) compared with never users, which is
consistent with the OR of 0.35 (0.17–0.71) found here.
The sum total of the worldwide evidence regarding endometrial
cancer and injectable progestagen-only contraceptives is based on
ten exposed cases; it broadly indicates a reduction in risk in users
but is not able to distinguish reliably the effects of injectable
contraceptives independent of previous combined oral contracep-
tive use [12,13,23]. A World Health Organization study based in
Thailand found an OR of endometrial cancer of 0.20 (0.03–1.63)
for users of injectable contraceptives exclusively versus never users
of hormonal contraceptives. However, all three cases exposed to
injectable contraceptives in this study had also used oestrogens
other than contraceptives pre-menopausally, so the role and
magnitude of the independent effect of injectable contraceptives
was unclear. A cohort study in China found a relative risk of 0.77
(0.34–1.76) in ever users versus never users of injectable
contraceptives [23]. The findings of the study presented here are
consistent with this evidence, with an OR of endometrial cancer of
0.36 (0.11–1.26) in long-duration users of injectable contraceptives
exclusively.
The findings reported here for oral contraceptive use in relation
to the risk of cancers of the breast, cervix, ovary, and endometrium
are broadly compatible with the well-established relationships
quantified to date [4,7,11,22]. For cervical cancer, the finding of
an increased risk with oral and/or injectable contraceptive use
within the last 10 y is comparable to recent pooled analyses for
oral contraceptive use [11]; the non-significant OR for use of oral
contraceptives exclusively should be viewed in the context of the
lack of a significant difference between the OR for exclusive users
of oral contraceptives, exclusive users of injectable contraceptives,
and users of both in the last 10 y and the fact that few women used
oral contraceptives exclusively (,10%) and for long durations. In
general, the patterns of risk associated with use of injectable
contraceptives are similar to those seen for combined oral
contraceptives.
The large numbers of women in this study, and the high
prevalence of use of injectable contraceptives, means that this
study is able to add to the existing evidence on the effects on
cancer risk of progestagen-only injectable contraceptives: the
dataset allowed us to examine risk separately in users of injectable
contraceptives exclusively, particularly for breast and cervical
cancer. The long duration of injectable contraceptive use in the
study participants also means the risks related to prolonged use
were able to be investigated. Although we were able to adjust for
multiple potential confounding factors, and sensitivity analyses
indicated robust findings in the face of additional adjustment, the
possibility that results were affected by uncontrolled confounding
cannot be excluded. Although the vast majority of the oral
contraceptives investigated here are likely to be combined oral
contraceptives, we cannot exclude the possibility that a small
proportion comprises progestagen-only preparations. Similarly, a
small proportion of the injectable contraceptives may be combined
oestrogen-progestagen preparations.
The Johannesburg Cancer Case Control Study has proven
valuable for investigation of other exposures and outcomes and has
been conducted efficiently for over 10 y in a resource-poor and
logistically difficult setting [16–18]. It is essentially a variant of the
hospital-based case–control study design, and can also be seen as
having characteristics in common with proportional mortality
analyses [19,24]. Using these methods, with controls being
individuals with cancers unrelated to the exposure under
investigation, the Johannesburg cancer study has successfully
investigated cancer risk in relation to human herpes virus 8 [16],
HIV [25], and tobacco smoking [25], producing findings that have
either been replicated in later studies or are in keeping with the
known evidence [26,27]. As well as its practicality in the South
African setting, the design also minimises problems associated with
referral bias. In keeping with other case–control studies, self-
reported exposures may be affected by recall bias; however, with
this design ‘‘controls’’ have cancer as well, which may attenuate
the problem, unless there is the perception that a specific cancer is
related to contraceptive use. Although we are unable to identify
any specific biases that this study design would be likely to
introduce, it is not possible to exclude entirely the possibility that
the findings observed here are influenced by unidentified biases or
other factors. The sensitivity analyses indicate that the choice of
individual cancers for inclusion in the control group did not have a
meaningful impact on the main results. Furthermore, the fact that
the patterns of cancer risk in relation to combined oral
contraceptive use observed here are similar to those in previous
studies is reassuring, and suggests that there is unlikely to be a
systematic or structural problem with the study methods. The
finding that the risks of breast and cervical cancer are increased
and the risks of ovarian and endometrial cancer are decreased with
exposure to hormonal contraceptives, using an identical set of
controls, is of particular importance in this respect, since
methodological problems or biases in control selection would
tend to produce results skewed systematically in one direction.
This study was designed a priori to focus on black women who
belong to a disadvantaged and under-researched community, but
nonetheless represent around 79% of the South African
population and 74% of the residents of Gauteng Province, where
the study was based [28]. While certain biological factors may vary
according to ethnicity, in South Africa access to services is still
heavily influenced by racial factors, such that only around 7% of
black individuals have medical insurance, compared to a large
majority in whites and an intermediate proportion in the Asian
Hormonal Contraceptives and Cancer in South Africa
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study to black women and recruitment through public sector
hospitals, which serve this largely uninsured group, minimises
potential confounding by racial, socioeconomic, and health-
services-related factors.
The hospitals that recruited for this study are the only public
tertiary referral hospitals for medical oncology and radiation
therapy in the study area. Current and historic referral patterns
mean that the patients constituting cancer cases and cancer
controls in this study should have similar probabilities of
presentation at these hospitals and recruitment into the study,
and this probability should not vary substantively according to
exposure to hormonal contraceptives. Additional adjustment for
socio-demographic factors, including education, urban/rural
residence, and province of birth further safeguards against this.
The cancer profile of the participants interviewed resembled the
background distribution of histologically reported cancers in black
women in South Africa in 2003, as reported to the pathology-
based South African National Cancer Registry [30]; the top five
cancers were as follows: cervix (33% [this study] versus 32%
[National Cancer Registry]), breast (26% versus 18%), oesophagus
(5.2% versus 4.8%), endometrium (3.1% versus 4.1%), and
colorectal (2.7% versus 2.1%). As the study was conducted in
tertiary referral hospitals, over 90% of cancers in study
participants were microscopically verified. In the absence of
cancer registries in the participating hospitals, it is not possible to
calculate overall response rates. From 5 January 2005 to 31
December 2006 at Charlotte Maxeke Johannesburg Academic
Hospital, of 1,853 women approached, 94 women did not
participate in the study. The reasons for non-participation were
as follows: out of age range (31%), unable to talk/deaf (4%), too
ill/dementia (20%), treatment already started (28%), refused (9%),
and other reasons (9%).
Oestrogens and progestagens exert different effects on different
tissues, and the exact mechanisms underlying their ability to
influence the risk of cancer are unclear. Combined oral
contraceptives and injectable progestagens exert their main
contraceptive effects via the suppression of ovulation, through
the feedback inhibition of follicle stimulating hormone and
luteinising hormone. Use of combined oral contraceptives
suppresses endogenous oestradiol, but this is essentially replaced
by exogenous oestradiol and, averaged over a cycle, the net
exposure to oestrogen in women taking these preparations may
not differ markedly from that in non-users [21]. Use of DMPA
results in varying degrees of suppression of oestradiol. While it has
been stated that oestradiol levels in users are generally maintained
at the early to mid-follicular level [31], other data indicate that
among women using DMPA and experiencing amenorrhoea, the
majority have oestradiol levels under 100 pmol/l, similar to
postmenopausal women [32]. Use also results in very high initial
serum levels of progestagen that diminish gradually following
administration, which is every 2 mo for norethisterone oenanthate
and every 3 mo for DMPA.
Oestrogens are known to increase the rate of cell division within
the ductal epithelium of the breast, and hence increase the
probability of a mutation occurring or of promotion of an existing
mutation; progesterone and progestagens may augment this effect
[4,6,21]. Data on hormonal therapy for the menopause indicate
that, in postmenopausal women, oestrogen in combination with
progestagen increases the risk of breast cancer to a much greater
extent than oestrogen alone [33,34]. This suggests an independent
effect of progestagens on breast cancer and is consistent with our
findings regarding progestagen-only injectable contraceptives. The
primary cause of cervical cancer is known to be infection with
oncogenic types of the human papillomavirus, but use of
combined oral contraceptives appears to act as a co-factor in
progression from infection to cervical cancer [35]. Since both
combined oral contraceptives and injectable prostagestagen-only
contraceptives suppress ovulation and gonadotrophin levels, these
are potential explanations for the observed preventative effect on
ovarian cancer. Combined oral contraceptives and injectable
progestagen-only contraceptives have atrophic and anti-prolifera-
tive effects on the endometrium; these effects are believed to
underlie their protective effects against endometrial cancer
[4,6,12,36].
The net effect on health of hormonal contraceptives includes
their intended highly effective contraceptive properties and a
range of side effects, some beneficial and some adverse. The
evidence from this study, in the context of the evidence to date,
indicates that the adverse effects of both oral and injectable
hormonal contraceptives on breast and cervical cancer are
transient, and risks in users return to those of never users within
10 y after stopping use. However, the exact time point at which
the risk in users returns to that in never users is not known.
Beneficial effects of both types of hormonal contraceptives on
ovarian and endometrial cancers are predominantly in long-
duration users.
Supporting Information
Figure S1 Sensitivity of cervical cancer main results to
the potential confounding effects of Pap smear frequen-
cy. Squares represent ORs, and horizontal lines indicate 95% CI.
Diamonds represent the ORs and confidence intervals for the
group comprising women from all three exposure categories
immediately above.
(TIF)
Figure S2 Sensitivity of cervical cancer main results to
the potential confounding effects of HIV status. Squares
represent ORs, and horizontal lines indicate 95% CI. Diamonds
represent the ORs and confidence intervals for the group
comprising women from all three exposure categories immediately
above.
(TIF)
Figure S3 Adjusted OR (95% CI) for breast cancer in
relation to use of oral and/or injectable contraceptives,
demonstrating the effect of removal of single specific
cancer types from the control group. Adjusted for age at
diagnosis, year of diagnosis, education, tobacco smoking, alcohol
consumption, parity/age at first birth, number of sexual partners,
urban/rural residence, and province of birth. Squares represent
ORs, and horizontal lines indicate 95% CI.
(TIF)
Figure S4 Adjusted OR (95% CI) for cervical cancer in
relation to use of oral and/or injectable contraceptives,
demonstrating the effect of removal of single specific
cancer types from the control group. Adjusted for age at
diagnosis, year of diagnosis, education, tobacco smoking, alcohol
consumption, parity/age at first birth, number of sexual partners,
urban/rural residence, and province of birth. Squares represent
ORs, and horizontal lines indicate 95% CI.
(TIF)
Figure S5 Adjusted OR (95% CI) for ovarian cancer in
relation to use of oral and/or injectable contraceptives,
demonstrating the effect of removal of single specific
cancer types from the control group. Adjusted for age at
diagnosis, year of diagnosis, education, tobacco smoking, alcohol
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urban/rural residence, and province of birth. Squares represent
ORs, and horizontal lines indicate 95% CI.
(TIF)
Figure S6 Adjusted OR (95% CI) for endometrial cancer
in relation to use of oral and/or injectable contracep-
tives, demonstrating the effect of removal of single
specific cancer types from the control group. Adjusted for
age at diagnosis, year of diagnosis, education, tobacco smoking,
alcohol consumption, parity/age at first birth, number of sexual
partners, urban/rural residence, and province of birth. Squares
represent ORs, and horizontal lines indicate 95% CI.
(TIF)
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Background. Hormonal contraceptives are among the
most commonly used medications. Globally, more than 210
million women currently use either hormonal contraceptive
pills or injectable contraceptives. Contraceptive pills usually
contain manmade versions of the female sex hormones
estrogen and progesterone (the combined oral contracep-
tive, or ‘‘pill’’); most injectable hormonal contraceptives
contain only manmade progesterone preparations. Hormonal
contraceptives, which prevent pregnancy by disrupting the
cyclical changes in estrogen and progesterone levels that
prepare the body for pregnancy, have revolutionized birth
control since they first became available in the early 1960s.
However, it is now known that taking the pill also influences
women’s risk of developing cancers of the female
reproductive system. Current and recent users have an
increased risk of developing breast and cervical cancer (the
cervix is the structure that connects the womb to the
vagina) compared to never users, although this increased
risk quickly disappears when women stop taking the pill.
By contrast, women who have used the pill have a
reduced risk of developing ovarian cancer and cancer of
the womb (endometrial cancer) compared to never users
that increases with the duration of pill use and persists for
many years after use ceases. These effects on reproductive
system cancers are thought to occur because these
cancers depend on naturally occurring sex hormones for
their development and growth.
Why Was This Study Done? Although the evidence that
the pill influences the risk of developing cancers of the
female reproductive system is extensive, much less is known
about how injectable hormonal contraceptives affect cancer
risk. In this hospital-based case–control study (a study that
compares the characteristics of people with and without a
specific condition), the researchers investigate the relation-
ship between the use of oral and injectable hormonal
contraceptives and cancers of the breast, cervix, ovary, and
endometrium among black South African women. Injectable
contraceptives have been used for longer in South Africa
than elsewhere and are used more commonly than oral
contraceptives among black South African women.
What Did the Researchers Do and Find? As part of the
Johannesburg Cancer Case Control Study, which recruits
black patients attending Johannesburg public referral
hospitals for cancer treatment, the researchers compared
hormonal contraceptive use in women with breast, cervical,
ovarian, or endometrial cancer with contraceptive use in
women diagnosed with other cancers such as lung, colon,
and rectal cancers, which are not known to be influenced by
hormonal contraceptives. Among the controls, a quarter had
used injectable contraceptives and a fifth had used oral
contraceptives. After adjusting for other factors that might
influence cancer risk such as age, smoking, and number of
sexual partners, the odds ratio (OR) of breast cancer among
current and recent users of oral and/or injectable
contraceptives compared to never users was 1.66. That is,
the risk of developing breast cancer among current and
recent users of hormonal contraceptives was 1.66 times that
among never users. For women using oral contraceptives
exclusively or injectable contraceptives exclusively, the ORs
of breast cancer were 1.57 and 1.83, respectively. There were
also increases in cervical cancer risk among current and
recent users of hormonal contraceptives compared to never
users, but no significant increase in breast or cervical cancer
risk among women who had ceased hormonal contraceptive
use more than ten years previously. Finally, the use of
hormonal contraceptives for more than five years reduced
the risk of both ovarian and endometrial cancer.
What Do These Findings Mean? These findings indicate
that, among black women in South Africa, the use of oral or
injectable hormonal contraceptives is associated with a
transiently increased risk of breast and cervical cancer, and
that extended use of these contraceptives is associated with
a reduced risk of ovarian and endometrial cancer. Moreover,
they suggest that the effects of oral versus injectable
contraceptives on cancer risk do not differ substantially,
although for endometrial and ovarian cancer the small
number of cases exposed to injectable contraceptives limits
the accuracy of the risk estimates. Other limitations of this
study include the possibility that the findings may be
affected by uncontrolled confounding. That is, women who
used hormonal contraceptives may have shared other
unidentified characteristics that affected their cancer risk.
Nevertheless, these findings provide new information about
the effects of oral and injectable hormonal contraceptives on
cancer risk that should help women make informed
decisions about their choice of contraceptive method.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001182.
N The US National Cancer Institute provides information on
breast cancer (including personal stories from breast
cancer survivors), cervical cancer, ovarian cancer, and
endometrial cancer for patients and health professionals,
and a fact sheet on oral contraceptives and cancer risk (in
English and Spanish)
N Cancer Research UK also provides information on breast
cancer, cervical cancer, ovarian cancer, and endometrial
cancer and information about the birth control pill and
cancer risk
N Eyes on the Prize, an online support group for women who
have had cancers of the female reproductive system, has
personal stories; further personal stories about breast,
cervical, and ovarian cancer are provided by the charity
Healthtalkonline
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